Mango Sciences, ImmunoACT Partner to Expand CAR-T Access in India

The partnership marks the first time globally that a value-based model has been attached to CAR-T therapy, a high-cost treatment that has historically been beyond reach for many cancer patients.

Mango Sciences and ImmunoACT have announced a partnership aimed at improving affordability and access to NexCAR19, India’s indigenous CAR-T therapy for leukaemia and lymphoma.

The collaboration introduces two financial support mechanisms for eligible patients: a 0% interest bridge financing plan of up to ₹10 lakh and a value-based offering of up to ₹10 lakh tied to clinical outcomes.

The partnership marks the first time globally that a value-based model has been attached to CAR-T therapy, a high-cost treatment that has historically been beyond reach for many cancer patients.

The offering will initially be available at select healthcare facilities administering NexCAR19.

NexCAR19, developed by Mumbai-based ImmunoACT, is India’s first commercial CAR-T therapy and has expanded the availability of cutting-edge cellular immunotherapy at a comparatively lower price point. With the new financing solutions, the companies aim to further reduce upfront cost barriers for patients undergoing treatment for certain blood cancers.

Mango Sciences, headquartered in Boston and Bengaluru, said the initiative leverages the company’s data and technology infrastructure to link affordability programs with real-world outcomes. “We are excited to bring our Value-Based offerings to CAR-T — a global first. We aim to utilise data science and technology to ensure patients can access the latest innovations in oncology,” said Dr. Mohit Misra, Founder and CEO of Mango Sciences.

ImmunoACT founder Dr. Rahul Purwar said the collaboration is designed to support patients who may struggle with the financial demands of CAR-T therapy. “The programs shall significantly help patients to afford our therapy, and are outcome-based, demonstrating our conviction and evidence of NexCAR19’s efficacy and safety,” he said.

Mango Sciences operates in the healthcare data and AI space, providing analytics and technology solutions to enhance patient representation and access. The company’s value-based offering model is designed to reduce out-of-pocket burden on cancer patients while enabling pharmaceutical companies to expand access sustainably.

ImmunoACT, a spin-out from IIT Bombay, has been developing cell and gene therapies for oncology indications and commercialised NexCAR19 as a domestically manufactured CAR-T product. The company continues to scale its manufacturing and clinical capabilities to expand availability across cancer centres in India.

Stay tuned for more such updates on Digital Health News